NCT07068191 - Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 19, 2025

Primary Completion Date

July 31, 2025

Study Completion Date

August 31, 2025

Conditions

Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)HepatomegalyNonalcoholic Fatty Liver (NAFL)Nonalcoholic Fatty Liver Disease (NAFLD)Fatty LiverFatty Liver, AlcoholicFatty Liver, NonalcoholicFatty Liver Disease

Interventions

COMBINATION_PRODUCT

"Dietary supplement Gepaktiv"

"Dietary supplement Gepaktiv 60 minutes before meals 2 capsules × 3 times/day"

DRUG

UDCA (Ursodeoxycholic acid)

UDCA 10-15 mg/kg/day

DRUG

Ademetionine

Ademetionine 800-1600 mg/day.

Trial Locations (1)

625000

RECRUITING

Tyumen State Medical University, Tyumen